EligibleTrials

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting · NCT05899608 · Interventional (participants receive a specific treatment) · Lead sponsor: Summit Therapeutics

View the official record on ClinicalTrials.gov →
Lung cancer

Interventions studied

Ivonescimab InjectionPembrolizumab Injection

What this trial is about

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 28 US states.

Showing 60 of 260 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.